Výsledky vyhledávání - David Readett
- Zobrazuji výsledky 1 - 3 z 3
-
1
Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage No... Autor Christian Manegold, Donald Gravenor, Donald Woytowitz, J. Mezger, Vera Hirsh, Gary Albert, Mohammed Al-Adhami, David Readett, Arthur Μ. Krieg, Cynthia G. Leichman
Vydáno 2008Artigo -
2
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer Autor C. Manegold, Nico van Zandwijk, A. Szczęsna, Petr Zatloukal, Joseph S. K. Au, Maria Błasińska-Morawiec, Piotr Serwatowski, Maciej Krzakowski, Jacek Jassem, E.H. Tan, Rebecca Benner, Antonella Ingrosso, Sandra J. Meech, David Readett, N. Thatcher
Vydáno 2011Artigo -
3
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis Autor Carlton Dampier, Marilyn J. Telen, Ted Wun, R. Clark Brown, Payal Desai, Fuad El Rassi, Beng Fuh, Julie Kanter, Yves D. Pastore, Jennifer Rothman, James G. Taylor, David Readett, Krupa M. Sivamurthy, Brinda Tammara, Li‐Jung Tseng, Jay N. Lozier, Helen Thackray, John L. Magnani, Kathryn L. Hassell
Vydáno 2022Artigo
Vyhledávací nástroje:
Související témata
Clinical endpoint
Internal medicine
Medicine
Randomized controlled trial
Chemotherapy
Discontinuation
Gastroenterology
Lung cancer
Oncology
Phases of clinical research
Adverse effect
Alternative medicine
Anesthesia
Breast cancer
Cancer
Cisplatin
Confidence interval
Environmental health
Gemcitabine
Hazard ratio
Interim analysis
Neutropenia
Pathology
Placebo
Population
Quartile
Subgroup analysis
Surgery
Taxane
Toxicity